Show Cart

More News

29 Jun 2018 Biogen Exercises Option to Increase Ownership in Samsung Bioepis
28 Jun 2018 Devonian Announces the Signing of a Non-Binding Letter of Intent with Folia Biotech to develop FB-631 in cancer immunotherapy
28 Jun 2018 MolMed and AbCheck sign a three-year Master Agreement for the development of new CARs targeting novel tumor antigens
28 Jun 2018 Akebia Therapeutics and Keryx Biopharmaceuticals to Merge, Creating a Fully Integrated Company Focused on the Development and Commercialization of Therapeutics for Patients with Kidney Disease
28 Jun 2018 NBE Therapeutics Closes a CHF 20 Million Financing by Novo Holdings A/S
28 Jun 2018 Lupin and Mylan Partner to Commercialize Enbrel® (Etanercept) Biosimilar
27 Jun 2018 GC LabCell and Feldan Therapeutics announce license agreement to develop next-generation NK cells for immunotherapy using Feldan Shuttle technology
27 Jun 2018 AbbVie and Calico Announce Extension of Groundbreaking Collaboration
27 Jun 2018 Skyhawk Therapeutics Announces Strategic Collaboration with Celgene to Discover and Develop Novel mRNA Splicing Modifiers using Skyhawk's STAR* Technology Platform
26 Jun 2018 Aerpio Announces Exclusive License Agreement with Gossamer Bio for AKB-4924, a First in Class Hypoxia-Inducible Factor-1 Alpha Stabilizer in Development for Inflammatory Bowel Disease
26 Jun 2018 Akero Therapeutics Closes $65 Million Series A Financing to Advance New Treatments for Serious Metabolic Diseases
25 Jun 2018 AbbVie and Calibr announce collaboration for next generation T-cell therapies
20 Jun 2018 TG Therapeutics and Novimmune SA Announce Global Agreement for Development and Commercialization of a Novel Anti-CD47/ Anti-CD19 Bispecific Antibody
19 Jun 2018 Kallyope and Novo Nordisk announce collaboration to discover novel therapeutics for obesity and diabetes
19 Jun 2018 NeuroVive out-licenses targeted LHON therapy to BridgeBio Pharma's new subsidiary Fortify Therapeutics
14 Jun 2018 Arsanis Out-Licenses Preclinical Stage Klebsiella pneumoniae Monoclonal Antibodies from ASN300 Program
11 Jun 2018 BridgeBio Pharma Enters into Agreement to Acquire Late Stage Therapy for Ultra-Rare Disorder from Alexion; Launches Origin Biosciences to Develop and Commercialize Therapy
11 Jun 2018 Nkarta Therapeutics Announces Exclusive License to Natural Killer Cell Technology From National University of Singapore and St. Jude Children’s Research Hospital
11 Jun 2018 Alexion and Complement Pharma Announce Partnership to Co-Develop Pre-Clinical Complement Inhibitor for Neurodegenerative Disorders
11 Jun 2018 Translate Bio Announces Agreement with Sanofi Pasteur to Develop Vaccines for Infectious Diseases using Novel mRNA Technology
08 Jun 2018 Ophthotech Enters into Gene Therapy Agreements with the University of Florida and the University of Pennsylvania
08 Jun 2018 Biogen Enters Exclusive Option Agreement to Acquire TMS’ Phase 2 Asset for Acute Stroke
06 Jun 2018 Microbiotica Enters into Microbiome Collaboration with Genentech
06 Jun 2018 Ionis Closes Strategic Collaboration with Biogen to Develop Drugs for a Broad Range of Neurological Diseases
05 Jun 2018 Hookipa and Gilead Enter into a Collaboration and License Agreement to Develop Immunotherapies Against HIV and Hepatitis B

Currencies

Shopping cart

Cart empty

Latest report

Featured Products

Latest Target Pipeline

Currencies

Shopping cart

Cart empty

Latest report

Featured Products

Latest Target Pipeline

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up
Top